Estromineral Serena Plus and Symptomatic Menopause
Launched by ROTTAPHARM · Nov 20, 2012
Trial Information
Current as of July 22, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • female menopausal age
- • more than 5 hot flushes/day
- • mood or sleep changes
- Exclusion Criteria:
- • hormone replacement therapy
About Rottapharm
Rottapharm is a global pharmaceutical company dedicated to the research, development, and commercialization of innovative therapeutic solutions across various medical fields. With a strong focus on enhancing patient care, Rottapharm leverages cutting-edge science and technology to address unmet medical needs, particularly in areas such as oncology, cardiology, and infectious diseases. Committed to rigorous clinical research and ethical practices, Rottapharm collaborates with healthcare professionals and regulatory bodies to ensure the highest standards of safety and efficacy in its products, ultimately striving to improve health outcomes and quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Siena, , Italy
Patients applied
Trial Officials
Vincenzo De Leo, MD
Principal Investigator
Siena University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials